RxDoctor Payments Data

Basem Alkurdi, MD

Hepatology · Tampa, FLNPI 1477520617

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $12,250 of the $18,291 with a category attached, or 67.0%. Shionogi Inc accounts for 79.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $14,863 and has fallen 97.0% since, to $449 in 2025.

$18,291in general payments, 2019–2025

Across 47 payments — averaging $389.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shionogi Inc$15K
  • Gilead$3K
  • Madrigal Pharmaceuticals$181
  • Johnson & Johnson$156
  • Boston Scientific$149
  • Veloxis Pharmaceuticals, Inc.$136
  • plus $583 from 11 others

What the payments were for

  • Consulting fees$2,85016%
  • Speaking & faculty fees$12,25067%
  • Travel & lodging$1,2127%
  • Food & beverage$1,94511%
  • Entertainment$340%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hepatology providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$56,902
Medicare patients
215
Services billed
493

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin213$657,806
RezdiffraResmetirom24$96,179
Envarsus XrTacrolimus93$92,650
VemlidyTenofovir Alafenamide34$46,114
Everolimus22$43,253
Tacrolimus282$40,340
Ursodiol166$23,544
LokelmaSodium Zirconium Cyclosilicate20$14,443
Entecavir54$7,631
Mycophenolic AcidMycophenolate Sodium38$7,583
Mycophenolate Mofetil116$7,559
Lamivudine HbvLamivudine18$6,441
Lactulose68$4,038
Budesonide DrBudesonide15$1,079
Azathioprine13$588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$102$657,806213 claims
Madrigal PharmaceuticalsRezdiffra$181$96,17924 claims
GileadVemlidy$2,571$46,11434 claims
AstraZenecaLokelma$26$14,44320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hepatology providers in Floridaon file to place this against a meaningful peer group, so we don't.

Other hepatology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →